This facilitates cancer cells to escape from destruction by the immune system, and could limit the therapeutic efficacy of current immunotherapies that target cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or programmed death ligand 1 (PD-L1)/programmed death 1 (PD-1) [4]. Here, CTLA4 is linked to cancer.